However, currently available clinical diagnostic biomarkers, such as SCC, CEA, CA125, and Cyfra21-1, exhibited inadequate sensitivity and specificity for NSCLC screening, particularly in early-stage patients5-7. The gene discussed is CEACAM5; the disease is non-small cell lung carcinoma.